Leverette (Ethinylestradiol, Levonorgestrel | Lactose)

The ethinylestradiol component provides estrogenic activity that stabilizes the endometrium, while levonorgestrel supplies progestogenic activity that suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). This dual action prevents ovulation, thickens cervical mucus, and makes the uterine lining less suitable for implantation.

The specific dosage regimen for Leverette is determined by the prescribing healthcare professional based on the product’s labeling and patient factors. Typically, combined oral contraceptives are taken once daily for 21 or 24 active tablets followed by a hormone‑free interval, but the exact schedule must be confirmed by the prescriber.

Leverette is intended for use only when a woman is not pregnant. If pregnancy occurs, the product should be discontinued immediately and medical advice sought. Use during breastfeeding is generally not recommended unless the benefits outweigh potential risks, and this decision should be made by a qualified clinician.

To place an order, submit an enquiry on the Leverette product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leverette contains the standard 30 µg ethinylestradiol dose combined with 150 µg levonorgestrel, a common formulation that offers reliable contraception with a well‑characterised safety profile. Compared with products using different progestogens (e.g., desogestrel or drospirenone), Leverette may have a slightly lower risk of weight gain but similar efficacy in preventing pregnancy.

Leverette tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Leverette is taken orally, usually with a glass of water, at the same time each day. The tablets are swallowed whole and should not be split, crushed, or chewed. Patients should follow the prescribed cycle, taking active tablets consecutively and observing any hormone‑free interval as directed by their healthcare provider.

The most serious risks include venous thromboembolism, arterial thrombosis, and severe hypertension, which can be life‑threatening. Additional rare but serious concerns are hepatic adenoma, gallbladder disease, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience unexplained leg pain, chest discomfort, severe headache, or visual changes.

Leverette is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking medications that significantly reduce its effectiveness, unless alternative contraception is used.